RESULTS	The frequency of grade 3/4 neutropenia ( 8 vs. 19 % ) and anemia ( 8 vs. 10 % ) and the number of hospitalization days per month of survival ( 4.71.3 vs. 6.31.6 days ; p = 0.431 ) were not significantly different between patients who received gemcitabine alone and those who received G+C .\